601 North Parkcenter Drive
BioCorRx, Inc. (OTC: BICX) is a healthcare solutions company on the leading edge of addiction treatment. The company has developed a treatment program that is used by various independently owned treatment centers throughout the United States to treat alcoholism and opioid addiction.
The program consists of two components:
BioCorRx, Inc. has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant significantly reduces cravings for alcohol or opioids for several months and as long as a year in some patients, depending on individual metabolism rates.
BioCorRx, Inc. also developed a counseling program that is tailored specifically to help those afflicted with addiction addicts prepare for life without abuse of their desired substance. Once a patient has received the implant, they are encouraged to enter the counseling program to maximize results.
BioCorRx, Inc.’s revolutionary addiction treatment program has a very high success rate as reported by patients in routine telephone and face to face interviews conducted by clinics using the program. The implant is administered as an outpatient procedure, and in most cases, patients do not need to miss more than one day of work. They are then able to enter the private counseling program without co-workers or family members knowing.
CEO: Brady Granier